 ImmunoGen, Inc. NASDAQ: IMGN shares are trading flat at 3.57 after the companys Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review. ImmunoGens BLA acceptance is for mirvetuximab soravtansine monotherapy in patients with folate. 